trending Market Intelligence /marketintelligence/en/news-insights/trending/NuULKWBwMrKKRMKDAtqxCQ2 content esgSubNav
In This List

Starpharma drug shows superior anti-tumor activity in studies

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Starpharma drug shows superior anti-tumor activity in studies

Starpharma Holdings Ltd.'s DEP irinotecan showed significantly better anti-tumor activity and increased survival rates in a variety of human colon cancer models.

The company was studying its drug against conventional irinotecan in a pre-clinical study. Irinotecan is a medication used to treat colon cancer and small cell lung cancer; it is sold under the Camptosar brand name.

DEP irinotecan is Starpharma's version of the conventional drug.

Based on the results, Starpharma is expediting the development of the drug and is scaling up the treatment for further pre-clinical studies prior to clinical trials.